Your browser doesn't support javascript.
loading
Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions.
Riess, Hanno; Prandoni, Paolo; Harder, Sebastian; Kreher, Stephan; Bauersachs, Rupert.
Afiliação
  • Riess H; Department of Haematology and Oncology, Charité - Universitätsmedizin Berlin, Germany. Electronic address: hanno.riess@charite.de.
  • Prandoni P; Arianna Foundation on Anticoagulation, Bologna, Italy.
  • Harder S; Institute of Clinical Pharmacology, University Hospital, Frankfurt, Germany.
  • Kreher S; Department of Haematology and Oncology, Charité - Universitätsmedizin Berlin, Germany.
  • Bauersachs R; Department of Vascular Medicine, Darmstadt, and Center for Thrombosis and Haemostasis, University Medical Centre, Mainz, Germany.
Crit Rev Oncol Hematol ; 132: 169-179, 2018 Dec.
Article em En | MEDLINE | ID: mdl-30447923
ABSTRACT
Patients with cancer are at high risk of developing venous thromboembolism (VTE). Although the recommended low molecular weight heparins (LMWHs) are more effective than vitamin K antagonists in treating VTE in patients with cancer, they have limitations and contraindications. Direct oral anticoagulants (DOACs) circumvent some of these limitations. Here, DOAC use for VTE treatment in patients receiving anticancer therapy is reviewed, focusing on metabolic and elimination pathways, potential drug-drug interactions and practical considerations. DOACs are typically substrates of the cytochrome P450-based metabolic pathways and/or ATP-binding cassette transporters. Although many cancer therapies influence these pathways, only a minority of these drugs interact with DOACs. Phase III DOAC trials provided encouraging safety and efficacy data for their use in cancer-associated thrombosis. Furthermore, numerous ongoing DOAC trials strive to gain a better understanding of the treatment of cancer-associated thrombosis and continue to support a role for DOACs in this setting.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interações Medicamentosas / Tromboembolia Venosa / Anticoagulantes / Neoplasias Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interações Medicamentosas / Tromboembolia Venosa / Anticoagulantes / Neoplasias Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article